Plain-English translation of NCT03708224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether — a medication that helps your immune system fight cancer — works better when given alone or combined with other immune-boosting drugs before you have surgery to remove head and neck cancer. Researchers want to see if this medication can help your body's immune system attack the cancer more effectively and make surgery safer and more successful.
Currently, people with advanced head and neck cancer typically have surgery first, followed by radiation or chemotherapy. This trial is exploring whether giving this treatment before surgery could help your immune system recognize and attack cancer cells more effectively, potentially leading to better outcomes and fewer cancer recurrences.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the study medication (either alone or in combination with other immune medications) intravenously over a 15-day period before your scheduled surgery. After surgery, you may receive additional doses of the medication for up to 12 weeks depending on which study arm you are assigned to. Throughout the trial, you will have blood tests, biopsies, and follow-up visits to monitor how the treatment affects your cancer and your immune system, with researchers tracking your health for at least 2 years after treatment.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Alain Algazi
Collaborators
Genentech, Inc., American Head and Neck Society
Enrollment target
~55 participants
Started
March 2019
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
UCSF HDFCCC Cancer Immunotherapy Program (CIP)
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.